Compare
Rani Therapeutics Holdings, Inc. vs NRX Pharmaceuticals, Inc. vs Bio Essence Corp vs Avenue Therapeutics, Inc.
| Latest fiscal year | Rani Therapeutics Holdings, Inc. RANI | NRX Pharmaceuticals, Inc. NRXP | Bio Essence Corp BIOE | Avenue Therapeutics, Inc. ATXI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $1.63M | $1.45M | $1.90M | $1.40M |
| Revenue growth (YoY) | +58.9% | n/a | +485.8% | n/a |
| Gross margin | n/a | 65.1% (computed) | 75.3% | n/a |
| Operating margin | n/m | n/m | 47.4% | -219.6% |
| Net margin | n/m | n/m | 47.2% | -207.2% |
| Net income | -$40.95M | -$28.62M | $896.2K | -$2.91M |
| EPS (Diluted) | -$0.45 | n/a | n/a | n/a |
| Operating cash flow | -$18.71M | -$14.11M | $1.57M | -$1.83M |
| Free cash flow | -$18.80M | n/a | n/a | n/a |
| Cash & equivalents | $18.62M | $7.80M | n/a | $2.85M |
| Total assets | $58.62M | $12.96M | $422.5K | $2.93M |
| Total liabilities | $17.11M | $28.89M | $2.50M | $1.10M |
| Shareholders' equity | $33.01M | -$15.94M | -$2.07M | $1.83M |
| Return on year-end equity | -124.1% | n/a | n/a | -158.8% |
| Shares outstanding | n/a | 31.73M | 38.01M | 3.18M |
Revenue, most recent five fiscal years
| Fiscal year | Rani Therapeutics Holdings, Inc. | NRX Pharmaceuticals, Inc. | Bio Essence Corp | Avenue Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $1.63M Ended 2025-12-31 | $1.45M Ended 2025-12-31 | $1.90M Ended 2025-12-31 | $1.40M Ended 2025-12-31 |
| 1 year earlier | $1.03M Ended 2024-12-31 | $0 Ended 2024-12-31 | $323.9K Ended 2024-12-31 | $0 Ended 2024-12-31 |
| 2 years earlier | $0 Ended 2023-12-31 | $0 Ended 2023-12-31 | $551.5K Ended 2023-12-31 | n/a |
| 3 years earlier | $0 Ended 2022-12-31 | n/a | $621.6K Ended 2022-12-31 | n/a |
| 4 years earlier | $2.72M Ended 2021-12-31 | n/a | $888.0K Ended 2021-12-31 | n/a |